Patents Assigned to ALK-Abelló A/S
-
Publication number: 20160151481Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).Type: ApplicationFiled: January 8, 2016Publication date: June 2, 2016Applicant: ALK-Abelló A/SInventors: Heather Michelle Webster, Jason Daniel Frey, Trena Larissa Repp, Craig T. Grass, David Rowles, Gary Smith, Domingo Barber Hernandez, Fernando Juan Vidales, Carmen Arteaga Vázquez, Juan Carlos Moreno Segura, Maria José Chamorro Salillas
-
Patent number: 9265824Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).Type: GrantFiled: June 3, 2011Date of Patent: February 23, 2016Assignee: ALK-Abello A/SInventors: Heather Michelle Webster, Jason Daniel Frey, Trena Larissa Repp, Craig T. Grass, David Rowles, Gary Steven Smith, Domingo Barber Hernandez, Fernando Juan Vidales, Carmen Arteaga Vazquez, Juan Carlos Moreno Segura, Maria Jose Chamorro Salillas
-
Patent number: 9259464Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).Type: GrantFiled: December 7, 2011Date of Patent: February 16, 2016Assignee: ALK-Abelló A/SInventors: Heather M. Webster, Jason Daniel Frey, Trena L. Repp, Craig T. Grass, David Rowles, Gary Smith, Domingo Barber Hernandez, Fernando Juan Vidales, Carmen Arteaga Vazquez, Juan Carlos Moreno Segura, Maria Jose Chamorro Salillas
-
Patent number: 9248097Abstract: The present invention relates to mucosal allergen-specific immunotherapy with a seasonal allergen, wherein the therapy is initiated after start of the pollen season of the seasonal allergen. Preferably, the seasonal allergen is provided in solid dosage form and is administered daily. Furthermore, advantageously, the same dose may be used throughout the treatment period since up-dosing is not required.Type: GrantFiled: April 8, 2009Date of Patent: February 2, 2016Assignee: ALK-ABELLO A/SInventors: Eike Gunther Wustenberg, Eckhard-Carl Albrecht Puchert
-
Publication number: 20140271722Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.Type: ApplicationFiled: May 27, 2014Publication date: September 18, 2014Applicants: ALK-Abello A/S, R.P. Scherer Technologies, LLCInventors: Henrik Hugo Jacobi, Annette Roemmelmayer Lundegaard, Christian Gauguin Houghton, Stig Aasmul-Olsen, Lise Lund Maerkedahl, Jan Sondergaard Andersen, Kerry Mallindine, Owen James Murray, Susan Gerrard Banbury, Desmond Yik Teng Wong, Lisa Marie Garrett, Michael Hall
-
Publication number: 20140206027Abstract: The invention relates to method for quantification of the absolute amount of allergen in an allergen sample comprising: a) providing a known amount of one or more allergen calibration standard peptide(s) having a sequence of amino acids which is identical with, and optionally unique for, a sequence to be found in the allergen to be quantified and optionally labelling said allergen calibration standard peptide(s), b) degrading the allergen sample to obtain a mixture of peptides, and optionally labelling said peptides with one or more labelling agent(s), wherein at least the peptides in the degraded allergen sample or the calibration standard peptides are labelled, and if both the peptides in the degraded allergen sample and the allergen calibration standard peptide(s) are labelled, the labelling agent(s) used for labelling the allergen calibration standard peptide(s) are different from the labelling agent(s) used for labelling the peptides of the degraded allergen sample, c) quantifying the absolute amountType: ApplicationFiled: March 5, 2014Publication date: July 24, 2014Applicant: ALK-Abelló A/SInventor: Ulla Seppälä
-
Publication number: 20140127298Abstract: The present invention relates to mucosal allergen-specific immunotherapy with a seasonal allergen, wherein the therapy is initiated after start of the pollen season of the seasonal allergen. Preferably, the seasonal allergen is provided in solid dosage form and is administered daily. Furthermore, advantageously, the same dose may be used throughout the treatment period since up-dosing is not required.Type: ApplicationFiled: January 10, 2014Publication date: May 8, 2014Applicant: ALK-ABELLO A/SInventors: Eike Gunther WUSTENBERG, Eckhard-Carl Albrecht PUCHERT
-
Patent number: 8703903Abstract: The invention relates to method for quantification of the absolute amount of allergen in an allergen sample comprising: a) providing a known amount of one or more allergen calibration standard peptide(s) having a sequence of amino acids which is identical with, and optionally unique for, a sequence to be found in the allergen to be quantified and optionally labelling said allergen calibration standard peptide(s), b) degrading the allergen sample to obtain a mixture of peptides, and optionally labelling said peptides with one or more labelling agent(s), wherein at least the peptides in the degraded allergen sample or the calibration standard peptides are labelled, and if both the peptides in the degraded allergen sample and the allergen calibration standard peptide(s) are labelled, the labelling agent(s) used for labelling the allergen calibration standard peptide(s) are different from the labelling agent(s) used for labelling the peptides of the degraded allergen sample, c) quantifying the absolute amount ofType: GrantFiled: September 1, 2006Date of Patent: April 22, 2014Assignee: ALK-Abello A/SInventor: Ulla Seppala
-
Publication number: 20140010845Abstract: The present invention relates to the treatment of a hypersensitivity immune response, such as allergic rhinitis or asthma, via bystander suppression by use of an antigen unrelated to the allergen triggering the hypersensitivity immune response in an individual to be treated, wherein the antigen is obtainable from the source material comprising the “triggering” allergen.Type: ApplicationFiled: October 14, 2011Publication date: January 9, 2014Applicant: ALK-ABELLO A/SInventors: Jens Brimnes, Kaare Lund
-
Patent number: 8551491Abstract: The present invention relates to processes for the preparation of a batch of an active pharmaceutical ingredient, e.g. an allergen product. The invention also relates to a container comprising cryogranules of a liquid composition of an allergen product, and to a cryogranule of an allergen product. The processes feature formation of cryogranules using a container having therein a cryogenic medium (e.g. liquid nitrogen) and storage of the cryogranules in the same container. The cryogranules obtained can be stored and handled without prior freeze-drying.Type: GrantFiled: November 12, 2010Date of Patent: October 8, 2013Assignee: Alk-Abello A/SInventors: Martin Richter-Friis, Signe Andersen Kolmos
-
Publication number: 20130216582Abstract: The present invention relates to antigens and methods for the suppression of a hypersensitivity immune response via bystander suppression with an antigen unrelated to the allergen triggering a hypersensitivity immune response such as an allergic response in an individual. Treatment regiments covering the administering the unrelated antigen to the oral cavity (e.g. sublingual mucosa) combined with the administration of the unrelated antigen to either the respiratory tract, gastro-intestinal tract or skin in a simultaneous, contemporaneous, separate or sequential manner is provided.Type: ApplicationFiled: October 14, 2011Publication date: August 22, 2013Applicant: ALK-ABELLO A/SInventors: Jens Brimnes, Kaare Lund
-
Publication number: 20130195902Abstract: Dander from the domestic cat (Felis domesticus) is one of the most common causes of IgE mediated allergy. The present invention relates to a recombinant folded Fel d 1 with molecular and biological properties similar to the natural counterpart and specifically a synthetic gene coding for a direct fusion of Fel d 1 chain 2 N-terminally to chain 1. E coli expression resulted in a non-covalently associated homodimer with an apparent molecular weight of 30 kDa defined by size exclusion chromatography, each 19177 Da subunit displayed a disulfide pattern identical to that found in the natural Fel d 1, and having identical fold of natural and recombinant Fel d 1. The, recombinant Fel d 1 provides for diagnosis and allergen specific immunotherapy of cat allergy.Type: ApplicationFiled: February 20, 2013Publication date: August 1, 2013Applicant: ALK-ABELLO A/SInventor: ALK-ABELLO A/S
-
Patent number: 8491911Abstract: This invention relates to the use of a pharmaceutical product comprising allergen and optionally an adjuvant for fast up-dosing in connection with allergy vaccination wherein a reduced number of injections are used. The invention also relates to the pharmaceutical product as such.Type: GrantFiled: October 15, 2009Date of Patent: July 23, 2013Assignee: Alk-Abello A/SInventors: Henrik Hugo Jacobi, Eike Gunther Wüstenberg, Lise Lund Mærkedahl
-
Patent number: 8492099Abstract: The invention relates to a method of measuring the immunological activity of a vaccine preparation in the form of a mixture of one or more allergenic enzyme(s) and an oxygen-containing metal salt adjuvant, wherein the mixture comprises a liquid phase and a solid phase, and wherein at least a part of the allergenic enzyme(s) is adsorbed to the solid phase, the method comprising the steps of measuring the enzymatic activity of the mixture in an enzyme activity assay, and using the measurement obtained as an indication of the immunological activity of the vaccine preparation, or using the measurement obtained for quantifying the amount of allergenic enzyme.Type: GrantFiled: November 23, 2006Date of Patent: July 23, 2013Assignee: Alk-Abello A/SInventors: Maria Mercedes Ferreras Goméz, Hans-Henrik Ipsen, Morten Jonas Maltesen, Rasmus Linnemann Krogh
-
Patent number: 8459046Abstract: The present invention relates to processes for the preparation of a batch of an active pharmaceutical ingredient, e.g. an allergen product. The invention also relates to a container comprising cryogranules of a liquid composition of an allergen product, and to a cryogranule of an allergen product. The processes feature formation of cryogranules using a container having therein a cryogenic medium (e.g. liquid nitrogen) and storage of the cryogranules in the same container. The cryogranules obtained can be stored and handled without prior freeze-drying.Type: GrantFiled: November 12, 2010Date of Patent: June 11, 2013Assignee: Alk-Abello A/SInventors: Martin Richter-Friis, Signe Andersen Kolmos
-
Patent number: 8329196Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.Type: GrantFiled: April 4, 2008Date of Patent: December 11, 2012Assignees: ALK-Abello A/S, R.P. Scherer Technologies, LLCInventors: Henrik Hugo Jacobi, Annette R. Lundegaard, Christian Gauguin Houghton, Stig Aasmul-Olsen, Lise Lund Maerkedahl, Jan Sondergaard Andersen, Kerry Mallindine, Owen James Murray, Susan Gerrard Banbury, Desmond Yik Teng Wong, Lisa Marie Garrett, Michael Hall
-
Patent number: 8312841Abstract: A method for culturing and producing mites, such as house dust mites, comprising culturing the mites in a suitable solid growth medium, under suitable conditions and for a suitable period of time in a suitable production room, characterized in that the mites are cultured in medium comprised within a closed bag.Type: GrantFiled: March 28, 2008Date of Patent: November 20, 2012Assignee: Alk-Abello A/SInventors: Carmen Arteaga Vazquez, Juan Carlos Moreno Segura, Fernando Juan Vidales, Maria Jose Chamorro Salillas
-
Publication number: 20120141536Abstract: The present invention relates to the use of a seasonal allergen composition for the manufacture of a vaccine formulation for preventing or treating allergy to the allergen composition in a subject by parenteral administration, wherein the vaccine formulation is administered in a dosage regimen comprising an up-dosing phase, wherein the up-dosing phase partly or wholly overlaps with the allergen season of the allergen composition.Type: ApplicationFiled: March 28, 2008Publication date: June 7, 2012Applicant: ALK-ABELLÓ A/SInventor: Eike Gunther Wustenberg
-
Publication number: 20120100164Abstract: The present invention relates to the treatment of a hypersensitivity immune response, such as allergic rhinitis or asthma, via bystander suppression by use of an antigen unrelated to the allergen triggering the hypersensitivity immune response in an individual to be treated, wherein the antigen is obtainable from the source material comprising the “triggering” allergen.Type: ApplicationFiled: October 14, 2011Publication date: April 26, 2012Applicant: ALK-ABELLO A/SInventors: Jens BRIMNES, Kaare Lund
-
Publication number: 20120100163Abstract: The present invention relates to antigens and methods for the suppression of a hypersensitivity immune response via bystander suppression with an antigen unrelated to the allergen triggering a hypersensitivity immune response such as an allergic response in an individual. Treatment regiments covering the administering the unrelated antigen to the oral cavity (e.g. sublingual mucosa) combined with the administration of the unrelated antigen to either the respiratory tract, gastro-intestinal tract or skin in a simultaneous, contemporaneous, separate or sequential manner is provided.Type: ApplicationFiled: October 14, 2011Publication date: April 26, 2012Applicant: ALK-ABELLO A/SInventors: Jens BRIMNES, Kaare LUND